Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Meyer

Showing results (471-480 of 510) with videos related to

Pageof 51
Sort By:
British Journal of Sports Medicine|July 21, 2022
International Olympic Committee (IOC) consensus statement on acute respiratory illness in athletes part 1: acute respiratory infectionsMartin Schwellnus, Paolo Emilio Adami, Valerie Bougault, et al.
The Lancet. Oncology|April 12, 2024
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trialAna Oaknin, Kathleen Moore, Tim Meyer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 4, 2019
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenibTim A Labeur, Sarah Berhane, Julien Edeline, et al.
Lancet (London, England)|April 25, 2017
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialAnthony B El-Khoueiry, Bruno Sangro, Thomas Yau, et al.
Frontiers in Immunology|April 1, 2022
SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral ImmunitySophie Steiner, Tatjana Schwarz, Victor M Corman, et al.
Liver Cancer|March 27, 2025
Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar CarcinomaGhassan K Abou-Alfa, Tim Meyer, Richard Kinh Gian Do, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|February 27, 2025
The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinomaSudha Kodali, Laura Kulik, Antonio D'Allessio, et al.
Liver Cancer|June 18, 2026
The 2024 International Liver Transplant Society and International Liver Cancer Association Consensus Recommendations for Liver Transplantation for Liver CancerSudha Kodali, Laura Kulik, Antonio D'Alessio, et al.
The Lancet. Oncology|December 1, 2023
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trialJosep M Llovet, Masatoshi Kudo, Philippe Merle, et al.
The New England Journal of Medicine|July 5, 2018
Cabozantinib in Patients with Advanced and Progressing Hepatocellular CarcinomaGhassan K Abou-Alfa, Tim Meyer, Ann-Lii Cheng, et al.
Pageof 51

Showing results (471-480 of 510) with videos related to

Sort By:
Pageof 51
British Journal of Sports Medicine|July 21, 2022
International Olympic Committee (IOC) consensus statement on acute respiratory illness in athletes part 1: acute respiratory infectionsMartin Schwellnus, Paolo Emilio Adami, Valerie Bougault, et al.
The Lancet. Oncology|April 12, 2024
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trialAna Oaknin, Kathleen Moore, Tim Meyer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 4, 2019
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenibTim A Labeur, Sarah Berhane, Julien Edeline, et al.
Lancet (London, England)|April 25, 2017
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialAnthony B El-Khoueiry, Bruno Sangro, Thomas Yau, et al.
Frontiers in Immunology|April 1, 2022
SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral ImmunitySophie Steiner, Tatjana Schwarz, Victor M Corman, et al.
Liver Cancer|March 27, 2025
Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar CarcinomaGhassan K Abou-Alfa, Tim Meyer, Richard Kinh Gian Do, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|February 27, 2025
The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinomaSudha Kodali, Laura Kulik, Antonio D'Allessio, et al.
Liver Cancer|June 18, 2026
The 2024 International Liver Transplant Society and International Liver Cancer Association Consensus Recommendations for Liver Transplantation for Liver CancerSudha Kodali, Laura Kulik, Antonio D'Alessio, et al.
The Lancet. Oncology|December 1, 2023
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trialJosep M Llovet, Masatoshi Kudo, Philippe Merle, et al.
The New England Journal of Medicine|July 5, 2018
Cabozantinib in Patients with Advanced and Progressing Hepatocellular CarcinomaGhassan K Abou-Alfa, Tim Meyer, Ann-Lii Cheng, et al.
Pageof 51